|
Name |
Verrucarin B
|
Molecular Formula | C27H32O9 | |
IUPAC Name* |
(1R,3R,8R,12S,14R,19E,21Z,25R,26S,27S)-5,14,26-trimethylspiro[2,10,13,17,24-pentaoxapentacyclo[23.2.1.03,8.08,26.012,14]octacosa-4,19,21-triene-27,2'-oxirane]-11,18,23-trione
|
|
SMILES |
CC1=C[C@@H]2[C@@]3(CC1)COC(=O)[C@@H]4[C@](O4)(CCOC(=O)/C=C/C=C\C(=O)O[C@H]5[C@]3([C@]6(CO6)[C@@H](C5)O2)C)C
|
|
InChI |
InChI=1S/C27H32O9/c1-16-8-9-26-14-32-23(30)22-24(2,36-22)10-11-31-20(28)6-4-5-7-21(29)35-17-13-19(34-18(26)12-16)27(15-33-27)25(17,26)3/h4-7,12,17-19,22H,8-11,13-15H2,1-3H3/b6-4+,7-5-/t17-,18-,19-,22-,24-,25-,26-,27+/m1/s1
|
|
InChIKey |
WUZWNHCQLPXCLS-HBGYRMRFSA-N
|
|
Synonyms |
Verrucarin B; PHV68JZ445; 2290-11-1; Verrucarin A, 2'-deoxy-2',3'-epoxy-, (2'S,3'R)-; VERRUCARIN B [MI]; UNII-PHV68JZ445; SCHEMBL258359; CHEMBL1079296; DTXSID701033950; Q27286564; (2'S,3'R)-2'-DEOXY-2',3'-EPOXYVERRUCARIN A
|
|
CAS | 2290-11-1 | |
PubChem CID | 46883075 | |
ChEMBL ID | CHEMBL1079296 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 500.5 | ALogp: | 2.1 |
HBD: | 0 | HBA: | 9 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 113.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 36 | QED Weighted: | 0.214 |
Caco-2 Permeability: | -5.361 | MDCK Permeability: | 0.00001840 |
Pgp-inhibitor: | 0.072 | Pgp-substrate: | 0.985 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.941 |
30% Bioavailability (F30%): | 0.261 |
Blood-Brain-Barrier Penetration (BBB): | 0.905 | Plasma Protein Binding (PPB): | 69.21% |
Volume Distribution (VD): | 1.209 | Fu: | 17.80% |
CYP1A2-inhibitor: | 0.113 | CYP1A2-substrate: | 0.162 |
CYP2C19-inhibitor: | 0.72 | CYP2C19-substrate: | 0.552 |
CYP2C9-inhibitor: | 0.766 | CYP2C9-substrate: | 0.007 |
CYP2D6-inhibitor: | 0.226 | CYP2D6-substrate: | 0.066 |
CYP3A4-inhibitor: | 0.895 | CYP3A4-substrate: | 0.512 |
Clearance (CL): | 4.633 | Half-life (T1/2): | 0.215 |
hERG Blockers: | 0.097 | Human Hepatotoxicity (H-HT): | 0.65 |
Drug-inuced Liver Injury (DILI): | 0.501 | AMES Toxicity: | 0.933 |
Rat Oral Acute Toxicity: | 0.675 | Maximum Recommended Daily Dose: | 0.925 |
Skin Sensitization: | 0.933 | Carcinogencity: | 0.059 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.211 |
Respiratory Toxicity: | 0.245 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004774 | 0.779 | D0Q4SD | 0.242 | ||||
ENC002240 | 0.746 | D06XHC | 0.233 | ||||
ENC003126 | 0.619 | D0C7JF | 0.226 | ||||
ENC003173 | 0.609 | D0Z4ZT | 0.219 | ||||
ENC004775 | 0.605 | D04GJN | 0.216 | ||||
ENC004446 | 0.580 | D0EP0C | 0.213 | ||||
ENC003943 | 0.571 | D0G8BV | 0.213 | ||||
ENC002026 | 0.556 | D0F1UL | 0.213 | ||||
ENC002050 | 0.446 | D02JNM | 0.212 | ||||
ENC003310 | 0.407 | D09WYX | 0.212 |